Matinas Biopharma Holdings, Inc. · AMEX:MTNB
Matinas Biopharma — Investor Presentation (October 2022)
31 slides from Matinas Biopharma's investor presentation, Oct 21, 2022
Slide 1: Matinas BioPharma Corporate Presentation
MATINAS | Corporate BIOPHARMA -__- Presentation October 2022
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, cash flow and other sta
Slide 3: Lipid Nanocrystal (LNC) Platform: Clinically Validated Intracellular Delivery
Lipid Nanocrystal (LNC) Platform: Clinically Validated Intracellular Delivery Next generation delivery - beyond LNPs and viral vectors Extra-hepatic Targeting Primary component (phosphatidylserine) facilitates preferential cellular uptake Demonstrated uptake by phagocytes and cells with externalized
Slide 4: What Are Lipid Nanocrystals (LNCs) and What Cargos Can They Deliver?
What Are Lipid Nanocrystals (LNCs) and What Cargos Can They Deliver? LNC Structure Calcium (Ca?*) ions Phosphatidylserine (PS) crystalline shell, engineered to self-assemble into nano-crystals in the presence of Ca?* Drug Cargo Cochleate Stable, phospholipid- calcium crystalline nanocrystals. Phosph
Slide 5: Phosphatidylserine Enables Intracellular Delivery
Phosphatidylserine Enables Intracellular Delivery Normally, PS is confined to the inner layer (facing cytosol) Cell membrane Infection Inflammation Injury Oncogenesis Phosphatidylserine (PS) With “activation” PS moves from the inner layer to the outer layer (cell membrane) Cell membrane COPYRIGHT MA
Slide 6: With Uptake via both Phagocytosis and Fusion
With Uptake via both Phagocytosis and Fusion, LNCs Potentially Target a Wide Array of Cells & Tissues PHAGOCYTOSIS FUSION Initiated by binding of PS to PS receptors Initiated by expression of PS on the surface of cells Nanocochleates e»® LNCs can fuse with cell Macrophages readily membranes and deli
Slide 7: Unlocking the Full Potential of the LNC Platform
Unlocking the Full Potential of the LNC Platform Matinas is working internally and with third parties to push Broad Therapeutic Applications the boundaries of LNC delivery Infection Immune Rx . Anti-infectives * Vaccines Present s Antivirals + Immune tolerance Intracellular Pulmonary Oncology . . *
Slide 8: LNCs: The Next Generation of Intracellular Nucleic Acid Delivery
LNCs: The Next Generation of Intracellular Nucleic Acid Delivery iy a Lipid Nanocrystals Lipid Nanoparticle Adeno-Associated Virus (LNCs) (LNP) (AAV) “Soral Dosing of 2 Proven Assets xX : Phagocytes & RES, spleen, liver *#) Target &/ activated cells xX uptake Not Orally Available Not Orally Availabl
Slide 9: Matinas' Pipeline and Discovery Programs: Internal and Collaborative
Matinas’ Pipeline and Discovery Programs: Internal and Collaborative Internal platform programs Undisclosed (LNC nucleic acids) mRNA, DNA Plasmids, Oligos ial Internal Programs |_| Joint Programs 9 COPYRIGHT MATINAS BIOPHARMA - 2022 Program Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Co
Slide 10: MAT2203
MAT2203 ORAL AMPHOTERICIN B Phase 3 to Commence Q1 2023 BIOPHARMA
Slide 11: MAT2203: Unmet Medical Need in Invasive Fungal Infections
MAT2203: Unmet Medical Need in Invasive Fungal Infections Available systemically and orally Cost- (i Potent - effective Fungicidal THE IDEAL ANTIFUNGAL AGENT Penetrates well into : Well-tolerated infected tissues and safe Low propensity for resistance Minimal drug-drug interactions for the treatment
Slide 12: MAT2203: A Novel Approach with a Proven Therapeutic Agent
12 MAT2203: A Novel Approach with a Proven Therapeutic Agent MAT2203 Oral amphotericin B formulation utilizing LNCs Initial indication in cryptococcal meningitis Efficient intracellular delivery to immune cells and delivery directly to infected tissues IMPROVED PROFILE LNC formulation enables oral a
Slide 13: Cryptococcal Meningitis Is a Severe Fungal Infection with High Mortality
Cryptococcal Meningitis ls a Severe Fungal Infection with High Mortality Deadly invasive fungal infection of the brain Typically affects immunocompromised individuals 10-20% 7,200 of all HIV-related Estimated incidence in deaths US and E5 combined 180,000 deaths per year worldwide Mortality VERY HIG
Slide 14: MAT2203: EnACT, a Successful Phase 2 Study
14 MAT2203: EnACT, a Successful Phase 2 Study COPYRIGHT MATINAS BIOPHARMA - 2022 EnACT INDUCTION (2 WEEKS) EARLY CONSOLIDATION (4 WEEKS) 1 MAT2203 4 MAT2203 + Fluconazole 5 days 10 days MAT2203 MAT2203 + Fluconazole (n=40) 2 days 13 days MAT2203 MAT2203 + Fluconazole ) SOHORT 3 IVAMB 1.2 e/day (£0)
Slide 15: EnACT Cohort Results
EnACT : Cohort 2 Results (Phase 3 Design Replicates Cohort 2) ENACT Clinical Data Validates the Use of the LNC Platform to Enable Oral Administration and Overcome Toxicity é —_ —. = —. - ) e O° e@ e All patients completin; MAT2203 was safe and Exceeded the primary P pleting No breakthrough i Hs indu
Slide 16: CSF Early Fungicidal Activity
CSF Early Fungicidal Activity log,, CFU /mL CSF/day ENACT EFA Comparisons Historical Fluconazole Monotherapy N=50 +: Treatment EFAs > O2are ; : associated with /ower mortality Historical, Fluconazole + SFC N=182 : -@- and improved clinical outcomes. : Beyond a O0.2threshold, no Concurrent Controls (
Slide 17: Key Secondary Efficacy Endpoint: Survival
Cohort 2 and Cohort 4 Key Secondary Efficacy Endpoint: Survival ™MAT2203 Cohort 2. = MAT2203 Cohort 4 = SoC 100 98 95 95 93 95 80 S 60 s g 40 n 20 ° Week 2 Week 4 Week 6 Week 10 Week 18 Primary Endpoint Secondary Endpoint (Phase 3) (Phase 3) n/N= 39/40? 38/40 38/40 39/402 37/40" 35/40 38/402 36/40*
Slide 18: Examples of Noteworthy Antifungal Activity in Patients with High Baseline Counts
18 Cohort 4 Examples of Noteworthy Antifungal Activity in Patients with High Baseline Counts QCC Result (CFU/mL) r 1 | Treatment: Intervention 715,000 120,000 2550 705 eo VISIT DAY Screening Day 4 Day 7 Day 14 QCC Result (CFU/mL) i 3 | Treatment: Intervention 330,000 7400 2650 e o e Screening Day8 D
Slide 19: EnACT Cohorts and Summary
EnACT Cohorts 2 and 4 Summary MAT2203 EnACT Phase 2 Trial Cohorts 2 and 4 EXCEEDED Positive impact on overall Favorable safety and tolerability primary endpoint threshold survival at all timepoints data support longer-term use of + Potent antifungal activity * 90%+ survival across cohorts MAT2203 wi
Slide 20: Phase III Pivotal Study Design - To Initiate Q1 2023
Phase III Pivotal Study Design - To Initiate Q1 2023 Assess MAT2203 as step-down therapy after 2 days of IV AMB for the Treatment of Cryptococcal Meningitis Validate results observed in EnACT Randomized 1:41:14 ratio to 1 of 2 MAT2203 arms or SoC SCREENING TREATMENT MAT2203 Induction/ Consolidation
Slide 21: Value Proposition for MAT2203
Value Proposition for MAT2203 on L release I ] enables longer treatment d enables e from hospital or avoidance Lu supported by oral of home infusion administration Prophylaxis in Transplant Patients Overall Development Strategy: Cryptococcal meningitis is a gateway indication, with plans to secure m
Slide 22: MAT2203: Potential for Treating Mucormycosis
MAT2203: Potential for Treating Mucormycosis Mucormycosis A life-threatening infection commonly caused by Rhizopus species, (Black Fungus) seen in immunocompromised patients, with mortality rates >50% to 100% Lung and Brain Fungal Knockdown in R. del _ Ara havaricin B sor MiCs in R. delemar nockdown
Slide 23: MAT2203: Addressing a $550M+ Market with Active Regional and Global Pharma
MAT2203: Addressing a $550M+ Market with Active Regional and Global Pharma Comparable Deals CioARA wi — scynexis Kopransor MAT2203 September 2019 February 2022 Cidara licenses ex-US / ex-Japan rights Scynexis licenses Greater China rights of Planned LCM expected of rezafungin to Mundipharma Ibrexafu
Slide 24: MAT2501 & Ongoing Partnership Programs
MAT2501 & ONGOING PARTNERSHIP PROGRAMS COPYRIGHT MATINAS BIOPHARMA - 2022 BIOPHARMA
Slide 25: MAT2501: NTM Program Overview and SAD Topline Results
MAT2501: NTM Program Overview and SAD Topline Results ¢ NTM organisms are a frequent cause of challenging pulmonary infections, especially in patients with pre- existing inflammatory lung diseases such as cystic fibrosis ‘ oti « LNC formulation enables oral administration, bioavailability and potent
Slide 26: LNC-remdesivir: In vivo Assessment of Efficacy Against SARS-CoV-2
Percent Starting Weight 26 LNC-remdesivir: /n vivo Assessment of Efficacy Against SARS-CoV-2 @ GILEAD In mice infected with SARS-CoV-2, oral LNC-Remdesivir reduced viral lung titers (beginning on Day 2), improved congestion scores, and mitigated weight loss 70 T T T T T T Days Post Infection @ Uninf
Slide 27: LNC-mRNA: Exclusive Research Collaboration with BioNTech
LNC-mRNA: Exclusive Research Collaboration with BioNTech sy es on mRNA and certain other nucleic acids MATINAS BIOPHARMA = $2.75 million upfront exclusive access fee plus research funding =" Ongoing license agreement negotiations =" BioNTech’s mRNA vaccine development expertise combined with Matinas
Slide 28: Expanding LNC Intellectual Property Portfolio
Expanding LNC Intellectual Property Portfolio Continuingly increasing our patent suite to increase protection and exclusivity Strong IP MAT2203 & 2501 potentially entitled to 12+ & years of exclusivity (QIDP & ODD status) Regulatory apts Designations CO Global Platform IP base protection out to 2037
Slide 29: Experienced Leadership Team
Experienced Leadership Team Executive Team Jerome D. Jabbour, J.D. Chief Executive Officer Thomas J. Hoover, MBA Chief Business Officer Theresa Matkovits, Ph.D. Chief Development Officer 20 *¥eunovion W Novartis eliant® : Ops ze. Keith A. Kucinski, CPA, MBA Hui Liu, Ph.D., MBA Raphael J. Mannino, Ph
Slide 30: Matinas Has Executed on Multiple Milestones... With More to Come
Matinas Has Executed on Multiple Milestones...... With More to Come MAT2203 LNC Platform & Collaborations 1H 2022 Milestones & Catalysts FDA approval on Phase 3 of EnACT Initiate preclinical studies in C. auris and mucormycosis Data available from Phase 1 SAD study in healthy volunteers Initiate & r
Slide 31: Matinas BioPharma Holdings
MATINAS BIOPHARMA Matinas BioPharma Holdings (NYSE AMER: MTNB) 1545 Route 206 South Suite 302 Bedminster, NJ 07921 (908) 484-8805 www.matinasbiopharma.com
Matinas BioPharma Holdings — Investor Presentation (October 2022) on 6ix